Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-04-28 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Ultomiris approved in the US for adults with gMG
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 6675J' and is dated '28 April 2022'. It announces a specific regulatory event: 'Ultomiris approved in the US for adults with generalised myasthenia gravis'. The text concludes with boilerplate language referencing RNS, the London Stock Exchange, and the Financial Conduct Authority (FCA). This structure is characteristic of a general regulatory news service announcement, which fits the definition of Regulatory Filings (RNS) as a primary category for official, non-standardized announcements distributed via an official news wire.
2022-04-28 English
ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCER
Foreign Filer Report
2022-04-27 English
Enhertu granted BTD for HER2-low breast cancer
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated through the Regulatory News Service (RNS). The content describes a specific regulatory action ('Breakthrough Therapy Designation granted in the US') for a drug ('Enhertu') and includes quotes from company executives and detailed scientific/trial information. This format is characteristic of a general regulatory announcement rather than a comprehensive financial report (like 10-K or IR) or a specific management/governance filing. Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIRS, DIV, CAP, etc.), the most appropriate classification is the general regulatory filing fallback.
2022-04-27 English
TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO
Foreign Filer Report
2022-04-25 English
Tremelimumab US Priority Review for Imfinzi combo
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement distributed via the RNS service of the London Stock Exchange. The content describes the acceptance of a Biologics License Application (BLA) by the US FDA for a drug combination (tremelimumab and Imfinzi) and provides clinical trial updates (HIMALAYA Phase III results). This is a specific corporate announcement regarding regulatory progress and clinical data, not a full annual report (10-K), an earnings release (ER), or a formal investor presentation (IP). Since it is a formal, time-sensitive announcement distributed through the RNS system that doesn't fit the other specific categories (like DIRS, DIV, or MANG), the most appropriate classification is the general regulatory announcement category, RNS.
2022-04-25 English
ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC
Foreign Filer Report
2022-04-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.